> Exhibit 99.2



> [PFIZER LOGO]
>         Pfizer Inc
>           235 East 42nd Street
>           New York, NY 10017
>           www.pfizer.com__________________Jeffrey B. Kindler
>           Chairman and CEODear Colleagues,
>     Im writing to update you on our progress in creating the worlds
>       premier biopharmaceutical company and, in particular, to share with you
>       some exciting news regarding our planning for the integration of Wyeth.
>     You will recall that when we embarked on Our Path Forward more than a year
>       ago, we emphasized our commitment to pursuing the very best and most forward-looking
>       science wherever it might exist  either within or outside of Pfizer.
>       In Wyeth, we found a partner whose capabilities and talents complement ours
>       beautifully. When Pfizer and Wyeth join together, we will be a much stronger
>       company that is able to fight disease in every way that science now allows
>        including through small molecules, large molecules and vaccines.
>     I want to compliment and thank the teams from both companies for their
>       dedication to the complex task of integration. Integration is a two-way
>       street, and we are adapting Pfizers organization  especially
>       our scientific and commercial operations  to capture the best of what
>       both companies offer.
>     The hard work of the integration teams has made it possible for the vast
>       majority of Pfizer colleagues to focus their time and attention on our current
>       business and on meeting the commitments that we have made to our stakeholders
>       for 2009. If you are not involved in integration planning, I remind you
>       that meeting those commitments on behalf of Pfizer  which remains
>       a company independent of Wyeth until closing  is your first and most
>       important priority.
>     We promised to keep you up to date on integration planning as decisions
>       are made. I am pleased to report that the planning is proceeding well. Our
>       progress affirms how well these two companies fit together, the value of
>       this combination and the commitment of leaders from both companies to address
>       complex integration issues openly, candidly and positively.
>     An important principle underlying our planning is our belief that it is
>       critical to have clear lines of accountability in place on the day the combined
>       company begins operating so as to minimize the disruptions and distractions
>       typically associated with integrations. In that regard, Im excited
>       to tell you today about a number of first-class Wyeth scientists and business
>       leaders who have agreed to join us, upon close, and the very positive impact
>       this will have on our science and our business. As planning continues, additional
>       appointments are expected that will enable Pfizer to begin appreciating
>       the benefits of the combined company with a new team and structure in place
>       immediately following the close of the acquisition.
>     A New Approach for Research
>     The science of biopharmaceutical research continues to change quickly and,
>       among the many exciting directions it is taking, two are particularly important
>       and promising. One pursues new medicines that are based on small molecular
>       weight drug discovery, and another looks for opportunities for medicines
>       that are based on large molecular weight drug discovery. To bring more innovative
>       medicines to more patients more quickly, we must have the ability to advance
>       on both fronts at once. Combining our scientists, scientific capabilities
>       and programs with those of Wyeth will give us a powerful opportunity to
>       do so. Thats why when this transaction closes, we will embark on a
>       unique approach to biomedical research that no other company in our industry
>       has taken.
>     Specifically, we are creating two distinct research organizations. The
>       PharmaTherapeutics Research Group will focus on discovery of small molecules
>       and related modalities, and Martin Mackay will lead it. This group will
>       continue to extend the strong legacy of both Pfizer and Wyeth in small-molecule
>       discovery. In addition, the PharmaTherapeutics Research Group will deploy
>       scientific Partner Lines to enable the delivery of the early-stage portfolios
>       of both research groups, as well as the late-stage portfolios of Pfizers
>       business units.
>     The BioTherapeutics Research Group will focus on large-molecule research,
>       including vaccines. Its leader will be Mikael Dolsten, who is currently
>       in charge of Wyeths research organization. Mikael has 20 years of
>       experience in the pharmaceutical industry, spanning R&D leadership in
>       numerous therapeutic areas including oncology, immunology, inflammation,
>       respiratory, cardiovascular, metabolic, central nervous system, gastrointestinal
>       and virology. He has held senior leadership roles at Pharmacia, AstraZeneca
>       and Boehringer Ingelheim. The group Mikael will lead will capitalize on
>       Wyeths industry-leading expertise in biologics and will build on the
>       momentum established both by the centers of large-molecule and pharmaceutical
>       science excellence in PGRD as well as by Pfizers Biotherapeutics and
>       Bioinnovation Center (BBC), which will remain a distinct federation of companies
>       within the BioTherapeutics Research Group. Combining the world-class talent
>       and expertise from the Wyeth, PGRD and BBC biotech groups will create an
>       organization with a world-class set of capabilities in vaccines, antibodies,
>       proteins, peptides, nucleic acids and other novel modalities.
>     Each of the two research groups will reflect the best of Pfizers
>       and Wyeths research talent to create a truly premier biopharmaceutical
>       research effort. Working in a coordinated, interdependent way under the
>       collaborative leadership of Martin and Mikael, both of whom will serve on
>       the Executive Leadership Team and report to me, these two groups will enable
>       us to accelerate our pursuit of disease targets, using the broadest scientific
>       arsenal possible.
>     Within the two research groups, small, targeted scientific teams 
>       focused on particular therapeutic areas or specific innovative technologies
>        will be led by world-class Chief Scientific Officers who will be
>       the single points of accountability for delivering medical advances. These
>       teams will be responsible for creating a rich portfolio of both small and
>       large molecules across both research organizations and, in particular, for
>       delivering positive proofs-of-concept for Pfizers business units to
>       develop. They will also aggressively pursue collaborations with top academic,
>       public sector and private sector institutions to accelerate research and
>       development of new medicines.
>     Additionally, we will create a team of top scientists from both companies
>       who will seek and evaluate new technologies, platforms, and pre-proof-of-concept
>       small and large molecules from external sources. As this group identifies
>       promising early-stage candidates from outside the company, it will collaborate
>       with our business development team to pursue these opportunities. By complementing
>       our internal research efforts, these scientists will help ensure that Pfizer
>       has access to the broadest set of early-stage compounds and technologies
>       available.
>     With the Wyeth acquisition, Pfizer will have the scientists and scientific
>       programs to make even greater advances in neuroscience and vaccines, among
>       other fields. We will welcome Emilio Emini, who currently heads Vaccine
>       R&D for Wyeth, to Pfizer as Chief Scientific Officer, Vaccine Research.
>       In addition, Menelas Pangalos, Wyeths Head of Discovery, will join
>       us as Chief Scientific Officer, Neuroscience Research.
>     The incomparable scientific expertise and outstanding leadership that Mikael,
>       Emilio and Menelas bring to Pfizer, combined with the outstanding scientists
>       in PGRD and the BBC, will help us build the worlds premier biopharmaceutical
>       R&D organization. As we continue our integration planning, we can look
>       forward to welcoming many more distinguished Wyeth scientists who will collaborate
>       with the extraordinary scientists at Pfizer.
>     This is a high-level overview, of course. Martin Mackay will provide our
>       research teams with greater detail in the coming days, demonstrating how
>       this approach builds on our current research model and moves us beyond it.
>       This approach will enable us to provide sharp focus, leadership and accountability
>       in drug discovery and will translate into high-impact new medicines for
>       patients. It will also ensure that our scientists are not encumbered by
>       the bureaucracy that slows down innovation.
>     Enhanced Commercial Operating Structure
>     Once the Wyeth acquisition closes, the new Pfizer will consist of nine
>       diverse global health care businesses, led by the presidents listed below.
>       Our commercial success depends on these businesses and their leaders, who
>       will have the freedom and accountability to operate their businesses in
>       accordance with the needs of distinct customers. In effect, they will function
>       as the chief executive officers of their business units. For organizational
>       purposes, they will report to one of two executive leaders on the ELT, who
>       will be responsible for identifying opportunities and challenges that exist
>       across business units, helping to set corporate priorities, and coaching
>       BU leaders.
>     Ian Read will assume the position of Group President, Pfizer BioPharmaceutical
>       Businesses, and will remain a member of the Executive Leadership Team reporting
>       to me. He will lead a group that includes five leading biopharmaceutical
>       businesses:
>     Primary Care, led by Olivier Brandicourt, will be the worlds
>         leading primary care business, with strong positions in cardiovascular
>         (#1), infectious disease (#2), immunology (#4) and central nervous system
>         diseases (#2), and with unique research and development opportunities
>         in areas like Alzheimers disease and pain.Specialty Care and Vaccines will be led by Geno Germano, currently
>         President of Wyeths U.S. and Pharmaceuticals business units. It
>         will be the worlds second largest specialty care business, with
>         prominent positions in inflammation (#2), vaccines (#4) and immunology
>         (#4); leading products such as Enbrel, the worlds leading biologic,
>         and Prevnar, the worlds leading vaccine; and a strong pipeline of
>         small- and large-molecule compounds.
>     Jim Connolly, currently Wyeths Executive Vice President & General
>       Manager, Vaccines, will join the Specialty Care and Vaccines BU reporting
>       to Geno. He will lead an integrated vaccine business comprising marketing,
>       sales and medical affairs, which will align closely with the Vaccine Research
>       group, led by Emilio Emini. They will partner to bring innovative new vaccines
>       to patients around the globe.
>     Emerging Markets will continue to be led by Jean-Michel Halfon
>         and will have a significantly enhanced presence in high-growth, less-developed
>         and underpenetrated markets, including those in Latin America, the Middle
>         East and China.Oncology will continue to be led by Garry Nicholson and will continue
>         to bring patients important treatments like Sutent. It will also bring
>         to market one of the most robust oncology product pipelines in the biopharmaceutical
>         industry, one that includes compounds focusing on diverse tumor types,
>         including lung, colorectal, liver, prostate and breast. Established Products will continue to be led by David Simmons and
>         will continue to be a strong global business in a marketplace that is
>         expected to see significant growth in the years ahead. Through portfolio
>         enhancement and expansion activities, including new partnerships, Established
>         Products will continue to extend Pfizers reach into this important
>         market segment.
>     Cavan Redmond, currently President of Wyeths Consumer Healthcare
>       business, will become Group President, Pfizer Diversified Businesses; he
>       will join the ELT and will report to me. This group will include four unique
>       businesses, each meeting important customer needs and offering significant
>       growth:
>     Animal Healthwill continue to be led by Juan-Ramón Alaix
>         and will have an enhanced leading position in the industry with important
>         large animal and companion animal products and a platform that includes
>         vaccines, parasiticides and anti-infectives. Capsugel will continue to be led by Guido Driesen and will continue
>         to be the world's pre-eminent manufacturer and developer of capsule products,
>         equipment and services for the pharmaceutical and associated health care
>         industries. Consumer Healthwill be led by Paul Sturman, currently President,
>         US and Global Business Development, New Products, for Wyeth Consumer Healthcare.
>         Paul is a Pfizer alumnus. Prior to joining Wyeth, he was President, North
>         America, Consumer Healthcare at Johnson & Johnson. Paul joined J&J
>         with their 2006 acquisition of Pfizer Consumer Healthcare (PCH), at which
>         time he was Senior Vice President, US Marketing, Canada & Caribbean
>         for PCH. Consumer Health will remain a leader in analgesics, cough/cold/allergy
>         and vitamin/nutritional supplements, including brands such as Advil, Caltrate,
>         Centrum, ChapStick, Robitussin and ThermaCare. Nutritional Health will be led by Erica Mann, currently Managing
>         Director of Wyeth Australia and New Zealand. Nutritional Health operates
>         in more than 50 countries and has a portfolio that includes a full line
>         of nutritional products, including infant formulas, follow-on formulas,
>         growing-up milks, and prenatal and adult supplements.
>     More New Medicines for Patients
>     All of these changes across Pfizer reflect the fact that science lies at
>       the heart of everything we do, and they support one goal: To bring more
>       new medicines and treatments to patients as quickly as possible, by the
>       means that works best for patients. After all, patients do not care whether
>       they are being treated by a small or large molecule. They just want to get
>       well, and well be more successful when we offer patients more unique
>       options.
>     Primary Care is a good example of what this means. This business unit is
>       investing in its Alzheimers disease portfolio to meet the growing
>       and changing needs of patients. In partnership with Eisai, Pfizer brings
>       to patients the leading product: Aricept. Several months ago, we launched
>       a partnership with Medivation to grow our Alzheimers portfolio by
>       developing Dimebon, a next-generation oral treatment for the disease. Similarly,
>       Wyeth has innovative programs in development, a strong partnership with
>       Elan and a potentially revolutionary biologic product in Phase III 
>       bapineuzumab  that could alter the progression of the disease. Together,
>       Pfizer and Wyeth will be able to attack Alzheimers disease in a number
>       of different ways. We will be able to reach a new level in Alzheimers
>       treatment much more quickly than either company would have been able to
>       do on its own.
>     We see similar examples across the company. In Specialty Care, for instance,
>       we will greatly enhance our ability to treat inflammation by adding Enbrel
>       to our portfolio and Wyeths development expertise in this field to
>       our JAK-3 program. And, when Wyeths Nutritional business works closely
>       with our Emerging Markets team, we will have the chance to dramatically
>       expand this growing business. Examples like these are just the beginning
>       of how the combined company will be able to do much more together.
>     There are similar opportunities in manufacturing and a number of partner
>       and platform lines and enabling functions. Our cultural aspirations 
>       to be customer- and science-driven, empowered, accountable and productive
>        remain unchanged. But this organizational approach to our scientific
>       and commercial teams is dramatically different from what any other biopharmaceutical
>       company has taken before, and it is a tribute to the breadth and diversity
>       of the future company that you and colleagues at Wyeth have helped to create.
>     Looking Ahead
>     As we move forward, our leaders will continue planning for the combination
>       of our companies and shaping their teams to meet the needs and expectations
>       of their unique customers through all stages of life  from prenatal
>       vitamins to treatments for pain and inflammation; from childhood immunizations
>       to treatments for Alzheimers disease. But, again, please remember
>       that until closing, the leaders named in this letter retain their current
>       responsibilities at their respective companies. And, let me repeat: No matter
>       where any of us works at Pfizer, nothing is more important right now than
>       meeting the commitments we made for 2009.
>     I have great respect for all of the men and women who work for Pfizer and
>       Wyeth. In particular, I would like to thank Bernard Poussot for his continued
>       strong leadership. He is an instrumental part of our integration efforts,
>       and his counsel is invaluable to me in shaping the new company.
>     I am personally grateful for all you are doing to put these two great companies
>       in position to join together. We are creating businesses that will have
>       an unrivaled ability to develop products and serve patients worldwide, and
>       this partnership simply would not be possible without your hard work and
>       commitment. Together, we are going to do great things to bring health solutions
>       to our world. Im tremendously excited about the opportunities that
>       lie ahead, and I hope you are too.
>     Sincerely,
>       /s/ JeffSubject to works councils and/or union consultations and
>       other legal requirements.
>     
>     # # # # #